0A45 Stock Chart & Stats
$55.19
$1.56(2.83%)
At close: 4:00 PM EDT
$55.19
$1.56(2.83%)
Day’s Range― - ―
52-Week Range$22.25 - $85.63
Previous CloseN/A
Volume42.49K
Average Volume (3M)50.84K
Market Cap
$21.75B
Enterprise Value$24.02K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Oct 29, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding396,786,250
10 Day Avg. Volume22,560
30 Day Avg. Volume50,838
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$48.92Price Target Upside-11.36% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-8.5
Revenue Forecast (FY)$2.11B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquidityMaterial cash reserves and an undrawn credit line give Moderna durable financing flexibility to fund near-term launches and pipeline programs. Low-to-moderate leverage noted in the balance sheet supports solvency while management executes commercial and clinical milestones over the next 2–6 months.
Regulatory And Commercial Momentum In Respiratory FranchisePositive regulatory outcomes and multi-country approvals underpin diversification beyond COVID Spikevax, supporting stable product revenue streams. A broader respiratory portfolio and joint procurement deals create structural commercial opportunity and durable market access across regions.
Improving Cost Efficiency And Operating DisciplineSustained reductions in cash cost, COGS, R&D and SG&A indicate management is aligning the cost base to a lower post-pandemic revenue run-rate. Structural cost discipline improves runway, supports margin recovery potential, and reduces the cash required to advance key programs over months.
Bears Say
Weak Cash Generation And Negative Free Cash FlowPersistent negative operating and free cash flow signals Moderna cannot fully self-fund development and commercial expansion. Even with improvement, ongoing cash burn constrains strategic optionality, increases reliance on cash reserves or financing, and pressures durability of investments.
Large Operating Losses And Material Litigation ImpactSubstantial quarterly losses combined with a near‑term, large litigation payment materially reduced liquidity and shorten the effective runway. These durable cash outflows limit flexibility to accelerate programs or commercial rollouts without careful capital allocation or external funding.
Clinical Development Setbacks And Timing UncertaintyA Phase III interim miss introduces program risk and prolongs timelines for potential approval and commercialization. Additional enrollment and seasonal accrual needs create durable uncertainty around milestone timing and potential revenue, affecting multiyear pipeline value realization.
Moderna News
0A45 FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest share price was $22.25 and its highest was $85.63 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $21.75B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 85 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.032 by $0.062.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.16.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.032. Following the earnings report the stock price went down -1.374%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in GB:0A45
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$48.92 (-11.36% Downside)
$48.92 (-11.36% Downside)
Blogger Sentiment
Bullish
GB:0A45 Sentiment 74%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 70%
Bearish news 30%
Bearish news 30%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
0A45 Company Deck
0A45 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all GB:0A45 earnings summaries0A45 Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
0A45 Stock 12 Month Forecast
Average Price Target
$48.92
▼(-11.36% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―